Did you mean isopropyl alcohol and amino associated virus?
Displaying drugs 14401 - 14425 of 15263 in total
IRX-5183
Investigational
Stannsoporfin
Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.
Investigational
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
MN-305
MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
Investigational
Matched Description: … MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by …
Biomed 101
Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
Investigational
Matched Description: … Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma …
Mirostipen
Investigational
Amperozide
Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication....
Experimental
Matched Description: … It inhibits dopamine release and alters the firing of dopaminergic neurons. ... amperozide's main use lies in veterinary medicine, where it is typically employed to minimize aggression and …
Deferitrin
Deferitrin is under investigation in clinical trial NCT00069862 (Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-thalassemia).
Investigational
Matched Description: … Deferitrin is under investigation in clinical trial NCT00069862 (Iron Balance Study of DFO and GT56-252 …
Ispronicline
Ispronicline is under investigation in clinical trial NCT00109564 (A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)).
Investigational
Matched Description: … Ispronicline is under investigation in clinical trial NCT00109564 (A Safety and Efficacy Study of Ispronicline …
Opiranserin
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of …
Tropifexor
Tropifexor is under investigation in clinical trial NCT02516605 (A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients).
Investigational
Matched Description: … investigation in clinical trial NCT02516605 (A Multi-part, Double Blind Study to Assess Safety, Tolerability and …
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
MPI-674
MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. It is...
Investigational
Matched Description: … MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability ... AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and …
AT1391
AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
Investigational
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Actelion-1
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
Pegpleranib
Investigational
5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID
Experimental
ATG002
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and...
Investigational
Matched Description: … factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and …
CRx-119
CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.
Investigational
Matched Description: … CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. …
SR 140333
SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.
Investigational
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … , that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and …
CAM-2029
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and …
Displaying drugs 14401 - 14425 of 15263 in total